Cell therapy CER-1236 put on FDA fast track as AML treatment
The U.S. Food and Drug Administration (FDA) has granted fast track designation to CER-1236, an experimental cell therapy that Cero Therapeutics is developing to…
Blood cancer is a broad term encompassing diseases in which blood cells grow too much or develop abnormally. Typically, blood cancers are classified into three main categories – leukemia, lymphoma, and myeloma – but they can be further divided into dozens of specific types, each with unique features.
Read moreA wide range of therapies are available for treating blood cancer, from chemotherapy and targeted therapy to radiation, stem cell transplant, and surgery. When devising a suitable treatment plan for blood cancer, healthcare providers take into account various factors, such as age, overall health, the specific type of blood cancer, and potential treatment side effects.
Read moreThe U.S. Food and Drug Administration (FDA) has granted fast track designation to CER-1236, an experimental cell therapy that Cero Therapeutics is developing to…
Xspray Pharma has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for its oral therapy XS003 (nilotinib) for the…
Biotech company Schrödinger said it’s discontinuing the development of SGR-2921, an experimental therapy for certain types of blood cancer, following the deaths of…
The U.S. Food and Drug Administration (FDA) granted fast track designation to birelentinib as a potential treatment for certain forms of blood cancer. The…
More people in Canada with the rare blood cancer Ph+ CML — fully, Philadelphia chromosome-positive chronic myeloid leukemia — in the…
The European Commission has approved Autolus Therapeutics’ cell therapy Aucatzyl (obecabtagene autoleucel) as a treatment for B-cell precursor acute lymphoblastic leukemia (B-ALL), an aggressive…